Malignant neoplasm of unknown primary site – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant neoplasm of unknown primary site – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment https://clinicaltrials.eu/trial/a-study-of-cldn6-car-t-cell-therapy-with-or-without-cldn6-rna-lpx-vaccine-in-patients-with-cldn6-positive-advanced-solid-tumors-that-returned-or-did-not-respond-to-treatment/ Wed, 29 Apr 2026 15:08:40 +0000 https://clinicaltrials.eu/trial/a-study-of-cldn6-car-t-cell-therapy-with-or-without-cldn6-rna-lpx-vaccine-in-patients-with-cldn6-positive-advanced-solid-tumors-that-returned-or-did-not-respond-to-treatment/ This study involves patients with solid tumors, which are cancers that form in organs and tissues of the body. The study is examining patients whose cancer has either come back after previous treatment or has not responded to earlier treatments. The treatment being tested is called BNT211, which is a type of cell therapy that uses specially modified immune cells from the patient’s own body. These cells are engineered to recognize and attack cancer cells that have a specific protein called CLDN6 on their surface. In some parts of the study, patients will receive this cell therapy alone, while in other parts, patients will receive the cell therapy together with a vaccine made from genetic material that may help the immune system work better against the cancer.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

]]> Study to Identify Unknown Primary Cancer Using [18F]-AlF-FAPI-74 PET-CT for Patients with Carcinoma of Unknown Primary https://clinicaltrials.eu/trial/study-to-identify-unknown-primary-cancer-using-18f-alf-fapi-74-pet-ct-for-patients-with-carcinoma-of-unknown-primary/ Wed, 29 Apr 2026 14:47:55 +0000 https://clinicaltrials.eu/trial/study-to-identify-unknown-primary-cancer-using-18f-alf-fapi-74-pet-ct-for-patients-with-carcinoma-of-unknown-primary/ This clinical trial is focused on a condition known as Carcinoma of Unknown Primary (CUP). This is a type of cancer where the primary origin of the tumor is not identified despite thorough testing. The study will use a special imaging technique called [18F]F-FAPI PET-CT to help locate the primary tumor in patients diagnosed with CUP. The treatment involves an injection of a solution called [18F]-AlF-FAPI-74, which is a chemical substance designed to help highlight cancer cells during the imaging process.

The purpose of the study is to determine how effective the [18F]F-FAPI PET-CT scan is in identifying the primary tumor in patients with CUP. Participants will receive an injection of the [18F]-AlF-FAPI-74 solution, followed by a PET-CT scan. This scan combines two imaging techniques, PET (Positron Emission Tomography) and CT (Computed Tomography), to provide detailed pictures of the inside of the body. The study aims to see if this method can accurately detect the primary tumor that other standard tests have not been able to find.

Throughout the study, some participants may receive a placebo instead of the active solution to compare the results. The trial will assess the ability of the [18F]F-FAPI PET-CT to correctly identify the primary tumor and evaluate its sensitivity and specificity, which are measures of how well the test can detect the disease and distinguish it from other conditions. The study is expected to continue until 2026, with recruitment starting in 2024.

]]> A Phase 1/2a Study of BNT142 Safety and Early Effectiveness in Patients with Advanced Solid Tumors Expressing CLDN6 Protein https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-bnt142-for-patients-with-advanced-ovarian-lung-or-testicular-cancer/ Wed, 29 Apr 2026 14:27:51 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-bnt142-for-patients-with-advanced-ovarian-lung-or-testicular-cancer/ This clinical trial studies a new treatment called BNT142 for patients with solid tumors. The study focuses specifically on advanced cases of ovarian cancer, lung cancer, and testicular cancer that are positive for a specific marker called CLDN6. The medication is given as a dispersion for injection through infusion.

The main purpose of this research is to test how safe BNT142 is and to see how well it works in treating these types of cancers. The study is divided into two parts. In the first part, different dose levels of the medication will be tested to find the most appropriate dose. The second part will look more closely at how well the treatment works in fighting the cancer.

During the study, patients will receive BNT142 treatment, and doctors will monitor their health and how their cancer responds to the medication. The treatment targets specific features of cancer cells, particularly a protein found on the surface of certain tumor cells. The study will track various measures of the treatment’s effectiveness, including whether tumors shrink or stop growing, and how long any positive effects last.

]]>